Technical analysis of Damora Therapeutics, Inc. (GLTO): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +10.86% |
| 1 year | +795.09% |
| 3 years | +72.95% |
| 5 years | -74.68% |
52-Week Range
| 52-week High | $38.33 |
| 52-week Low | $2.01 |
| Avg Volume (90d) | 887K |
Technical Indicators
| SMA 50 | $26.34 |
| SMA 200 | $13.11 |
| Beta | 1.57 |
| 30-day Volatility (annualised) | 125.1% |
| Price vs SMA 50 | -3.2% |
| Price vs SMA 200 | +94.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $7.32 | |
| 2025-11 | $17.78 | +142.9% |
| 2025-12 | $23.01 | +29.4% |
| 2026-01 | $26.24 | +14.0% |
| 2026-02 | $29.58 | +12.7% |
| 2026-03 | $25.51 | -13.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $21.58 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.68 |
| EV / EBITDA | 1.90 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 19.73 |